Press release
Successful Conclusion of the Alzheimer's Association International Conference (AAIC) 2024: BestCovered Announces Initiative for Cognitive Screening of 100,000 Individuals in China
Image: https://www.getnews.info/uploads/47f02c906aa8d279be1b78b26260fc3b.jpg
Image: https://www.getnews.info/uploads/2902bb595fa285b8d9474341a3489f74.jpg
Innovative Drug Developments: LeqembiLecanemaband KisunlaDonanemab
A highlight of the conference was the presentation by Eisai and Lilly on their groundbreaking Alzheimer's disease treatments, Leqembi and Kisunla. These studies revealed significant progress in clearing amyloid plaques from the brain, thereby slowing disease progression. Particularly noteworthy was Leqembi's sustained efficacy over 18 months, demonstrating significant reduction in tau protein accumulation. Additionally, findings underscored the importance of early intervention, as patients with lower initial amyloid levels experienced superior outcomes.
Image: https://www.getnews.info/uploads/95a430ffbbb63a0fdd39a1a9e44c0ac7.jpg
Advancements in Biological Markers and Precision Diagnostics
The conference highlighted the potential of blood markers as a more affordable and accessible diagnostic tool, moving beyond traditional methods like PET-CT scans. Specifically, Plasma p-tau217 emerged as a recommended diagnostic indicator for Alzheimer's disease as per the National Institute on Aging/Alzheimer's Association (NIA-AA) guidelines, with related products receiving FDA designation. Dr. Jun Xu, Chief Physician of Neurology at Beijing Tian Tan Hospital, emphasized the non-invasive nature and cost-effectiveness of this blood test, highlighting its potential for treatment efficacy assessment and disease progression monitoring.
Digital Biomarkers: Revolutionizing Early Detection
Sessions on digital biomarkers underscored the importance of language-based indicators in detecting the earliest signs of cognitive disorders. BestCovered, the world leader in language digital biomarker-based screening, presented several research findings. The company is poised to further advance the development of cognitive disorder language digital biomarkers through collaborations with multilingual researchers worldwide.
Image: https://www.getnews.info/uploads/05c4ba5aaaa6cb44288c582097e8ad8e.jpg
Decoding Alzheimer's Disease Risk Factors
The Lancet unveiled a comprehensive report during the conference, updating the list of major modifiable risk factors for dementia to include visual impairment and high low-density lipoprotein cholesterol levels, expanding the total to 14. Notably, risk factors previously considered relevant only in old age, such as smoking and physical inactivity, were reclassified to midlife. This shift emphasizes the importance of initiating screening and interventions in midlife to potentially prevent approximately 45% of dementia cases.
Image: https://www.getnews.info/uploads/857c54b3d64d5b0801b46ce3c83b870d.jpg
Multi-dimensional Non-pharmacological Intervention Strategies
Non-pharmacological interventions took center stage, with researchers from around the globe sharing innovative practices. A Japanese research team demonstrated significant socio-economic benefits through an 18-month multidimensional intervention program for patients with mild cognitive impairment. Finnish studies showed lasting positive impacts on motor function and overall health levels even 11 years post-intervention. An Australian team's online multidimensional intervention approach proved effective in improving cognitive function and reducing cognitive disorder risks over three years of follow-up. Professor Henry Brodaty praised BestCovered's online intervention strategy, noting its potential to conserve social resources and enhance access to intervention services for older populations.
Image: https://www.getnews.info/uploads/c958c925eccd4b8e355746a044b2666f.jpg
Brain and Body Rehab Training (BBRT), a cognitive assessment and training software, stands out as a digital therapeutic solution that has secured the Class II Medical Device Registration Certificate from the NMPA and certification from the FDA. BBRT focuses on computerized cognitive training, augmented by interventions such as home-based exercises, dietary counseling, and strategies for managing chronic diseases. BBRT helps users adopt positive brain usage habits and embrace a healthier lifestyle, effectively reducing the risk of developing cognitive impairment.
Image: https://www.getnews.info/uploads/0498707f6965b79dacc8cf753b5a3edd.jpg
Bestcovered will initiate a cognitive screening targeting 100,000 people across China
AAIC2024 served as a testament to the power of global collaboration in advancing Alzheimer's research. As the sole entity specializing in cognitive impairment to achieve dual certification from both the FDA and NMPA, Bestcovered has delivered cognitive impairment risk assessment and early intervention services to more than 20 million individuals. In anticipation of World Alzheimer's Month, Bestcovered plans to harness its expertise in screening tools and partner with governments, academic institutions, healthcare facilities, and corporations to initiate a cognitive screening targeting 100,000 people across China. Moving forward, Bestcovered remains committed to fostering innovation and collaboration, enhancing partnership communication with international counterparts to advance cognitive impairment research collectively.
Media Contact
Company Name: Bestcovered
Contact Person: Zoey Zhuang
Email: Send Email [http://www.universalpressrelease.com/?pr=successful-conclusion-of-the-alzheimers-association-international-conference-aaic-2024-bestcovered-announces-initiative-for-cognitive-screening-of-100000-individuals-in-china]
Phone: 18049739109
City: Shanghai
Country: China
Website: https://www.bestcovered.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Successful Conclusion of the Alzheimer's Association International Conference (AAIC) 2024: BestCovered Announces Initiative for Cognitive Screening of 100,000 Individuals in China here
News-ID: 3634619 • Views: …
More Releases from Getnews
Spectrum Electric Redefines What It Means to Be a Full-Service Electrical Partne …
Image: https://www.globalnewslines.com/uploads/2025/12/f1b1018646e29745b0c22c200a9eee9e.jpg
Spectrum Electric, a Central Florida-based electrical contractor led by CEO Richard Forthman, is gaining regional attention for its proactive, client-focused approach to electrical service and commercial construction.
With more than 15 years in business and significant growth under Forthman's leadership over the past eight years, Spectrum Electric has positioned itself as an up-and-coming regional leader in the electrical contracting industry. While the company maintains a strong residential and service footprint…
The U.S. Green Card: Turning a Temporary Stay into a Permanent American Future
Image: https://www.globalnewslines.com/uploads/2025/12/1766183100.jpg
For many people, a U.S. visa is only the beginning. What they truly want is certainty - the ability to live, work, and plan their future in the United States without expiry dates, renewals, or ongoing fear that a single decision could unravel years of effort.
That certainty is called a Green Card.
Yet despite its importance, the Green Card [https://larhdellaw.com/] process is often misunderstood. Some believe it is only for…
The L-1 Visa: How Global Businesses Expand to the U.S. Without Starting From Scr …
Image: https://www.globalnewslines.com/uploads/2025/12/1766182907.jpg
For international companies with ambitions to enter the United States, few visa options are as powerful - or as misunderstood - as the L-1 Intracompany Transfer Visa.
When used correctly, the L-1 visa allows established businesses to expand into the U.S. market, transfer trusted senior staff, and build a long-term American presence without relying on lotteries, third-party sponsors, or speculative investment routes. When used incorrectly, it becomes one of the…
The B-1/B-2 Visitor Visa: Why Careful Preparation Matters More Than Ever
Image: https://www.globalnewslines.com/uploads/2025/12/1766182346.jpg
The B-1/B-2 visitor visa [https://larhdellaw.com/]is often described as the most common U.S. visa. That description, while true, can be misleading. Its familiarity causes many applicants to underestimate how closely these visas are scrutinised - and how easily an application can be refused.
In today's immigration environment, visitor visas are assessed with a level of caution that surprises even experienced international travellers. The rules themselves have not dramatically changed, but how…
More Releases for Alzheimer
Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928
Key Takeaways
• Disease-modifying…
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
